Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
Open Access
- 17 February 2011
- journal article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 70 (4), 583-589
- https://doi.org/10.1136/ard.2010.139774
Abstract
To evaluate the effect of different concomitant disease modifying antirheumatic drugs (DMARDs) on the persistence with antitumour necrosis factor (anti-TNF) therapies in patients with rheumatoid arthritis (RA). This analysis included 10 396 patients with RA registered with the British Society for Rheumatology Biologics Register, a prospective observational cohort study, who were starting their first anti-TNF therapy and were receiving one of the following DMARD treatments at baseline: no DMARD (n=3339), methotrexate (MTX) (n=4418), leflunomide (LEF) (n=610), sulfasalazine (SSZ) (n=308), MTX+SSZ (n=902), MTX+ hydroxychloroquine (HCQ) (n=401) or MTX+SSZ+HCQ (n=418). Kaplan-Meier survival analysis was used to study the persistence with anti-TNF therapy in each DMARD subgroup up to 5 years. Multivariate Cox proportional hazard models, stratified by anti-TNF used and start year and adjusted for a number of potential confounders, were used to compare treatment persistence overall and according to the reason for discontinuation between each of the DMARD subgroups, using MTX as reference. One-year drug survival (95% CI) for the first anti-TNF therapy was 71% (71% to 72%) but this dropped to 42% (41% to 43%) at 5 years. Compared with MTX, patients receiving no DMARD, LEF or SSZ were more likely to discontinue their first anti-TNF therapy while patients receiving MTX in combination with other DMARDs showed better treatment persistence. These results support the continued use of background DMARD combinations which include MTX. Consideration should be given to the discontinuation of LEF and SSZ monotherapy at the time anti-TNF therapies are started, with the possible exception of the SSZ+ETN combination.This publication has 31 references indexed in Scilit:
- Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alphaClinical Rheumatology, 2010
- A Systematic Review and Meta‐analysis of the Efficacy and Safety of Etanercept for Treating Rheumatoid ArthritisScandinavian Journal of Immunology, 2009
- Comparative effectiveness of tumour necrosis factor inhibitors in combination with either methotrexate or leflunomideAnnals Of The Rheumatic Diseases, 2009
- Efficacy of Biologicals in the Treatment of Rheumatoid ArthritisPharmacology, 2008
- The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based studyAnnals Of The Rheumatic Diseases, 2008
- The efficacy of inhibiting tumour necrosis factor and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisonsRheumatology, 2007
- Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease‐modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2006
- Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparisonAnnals Of The Rheumatic Diseases, 2006
- Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis.2005
- Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis.2005